![]() In Q4 2021, Blueprint's collaboration revenue increased more than threefold to $87.0 million from $27.4 million in the prior year. She also noted that the "improving COVID landscape" will allow patients to return to regular visits with hematologists in the US and aid the company's efforts to identify patients eligible for Ayvakit. "Key drivers of our performance will be growth in new patient starts and increasing treatment duration, which we anticipate will drive acceleration in revenue, particularly as we approach the second half of the year," Rossi said. In 2022, the company expects Ayvakit revenues of $115 to $130 million, more than doubling Ayvakit revenues in 2021. Christina Rossi, Blueprint's chief commercial officer, said Ayvakit's revenue from the advanced SM indication grew 55 percent sequentially between Q3 and Q4 in 2021, making this market the primary revenue driver for the drug. The US Food and Drug Administration approved Ayvakit for SM last June. The drug is approved in the US for unresectable or metastatic gastrointestinal stromal tumors with PDGFRA exon 18 mutations and for advanced systemic mastocytosis, or SM, a blood disorder driven by the KIT D816V mutation that can become cancerous. Blueprint's Q4 performance beat analysts' consensus revenue estimate of $102.7 million.ĭuring the quarter, the firm recorded a threefold increase in Ayvakit sales compared to revenues of $6.7 million in the year-ago quarter. The Cambridge, Massachusetts-based company more than tripled its revenues in Q4 2021 compared to Q4 2020, when it reported $34.1 million in revenue. NEW YORK – Blueprint Medicines on Wednesday reported fourth quarter revenues of $107.0 million, including $20.0 million from sales of Ayvakit (avapritinib) and $87.0 million in collaboration revenues. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |